tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Buy Rating for Merit Medical Systems Driven by New CEO Appointment and Strong Revenue Guidance

Buy Rating for Merit Medical Systems Driven by New CEO Appointment and Strong Revenue Guidance

Analyst Michael Matson of Needham reiterated a Buy rating on Merit Medical Systems, retaining the price target of $108.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Michael Matson has given his Buy rating due to a combination of factors, including the recent appointment of Martha Aronson as the new CEO of Merit Medical Systems. Aronson’s extensive experience in leadership roles at prominent healthcare companies is expected to bring valuable insights and strategic direction to MMSI. Her background includes significant tenures at Hill-Rom Holdings and Medtronic, as well as her role as Chair of the Board at CONMED Corporation.
Additionally, Merit Medical Systems has provided guidance for its second-quarter 2025 revenue to be above market expectations, projecting a 12-14% year-over-year increase. This positive outlook, coupled with the anticipated positive reception of the new CEO by investors, supports Matson’s confidence in the company’s growth prospects and underpins his Buy rating.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MMSI in relation to earlier this year.

Disclaimer & DisclosureReport an Issue

1